DAFTAR PUSTAKA

Alame-Emane, A. K., X. Guo, H. E. Takiff, and S. Liu. 2021. “Highly Transmitted M. Tuberculosis Strains Are More Likely to Evolve MDR/XDR and Cause Outbreaks, but What Makes Them Highly Transmitted?” *Tuberculosis* 129:102092. doi:10.1016/j.tube.2021.102092.

Al-Halifa, Sami, Mario Gauthier, David Arpin, Steve Bourgault, and Denis Archambault. 2019. “Nanoparticle-Based Drug Delivery Systems for Treatment of Infectious Diseases.” *Journal of Controlled Release* 306:164–86. doi:10.1016/j.jconrel.2019.05.011.

Batt, S. M., and et al. 2020. “Targeting the Arabinan Biosynthesis Pathway for Tuberculosis Therapy.” *Antimicrobial Agents and Chemotherapy* 64(4):e02120-19. doi:10.1128/AAC.02120-19.

Choi, S. H., and et al. 2022. “Targeted Nanoparticle Delivery Systems for Tuberculosis Therapy.” *Pharmaceutics* 14(1):123. doi:10.3390/pharmaceutics14010123.

Danhier, Fabienne, Eduardo Ansorena, Joana M. Silva, Régis Coco, Aude Le Breton, and Véronique Préat. 2012. “PLGA-Based Nanoparticles: An Overview of Biomedical Applications.” *Journal of Controlled Release* 161(2):505–22.

Dheda, Keertan, Tawanda Gumbo, Gary Maartens, Kelly E. Dooley, Ruth McNerney, Megan Murray, Jennifer Furin, Edward A. Nardell, Leslie London, Erica Lessem, Grant Theron, Paul van Helden, Stefan Niemann, Matthias Merker, David Dowdy, Annelies Van Rie, Gilman K. H. Siu, Jotam G. Pasipanodya, Camilla Rodrigues, Taane G. Clark, Frik A. Sirgel, Aliasgar Esmail, Hsien-Ho Lin, Sachin R. Atre, H. Simon Schaaf, Kwok Chiu Chang, Christoph Lange, Payam Nahid, Zarir F. Udwadia, C. Robert Horsburgh Jr, Gavin J. Churchyard, Dick Menzies, Anneke C. Hesseling, Eric Nuermberger, Helen McIlleron, Kevin P. Fennelly, Eric Goemaere, Ernesto Jaramillo,

Marcus Low, Carolina Morán Jara, Nesri Padayatchi, and Robin M. Warren. 2017. “The Epidemiology, Pathogenesis, Transmission, Diagnosis, and Management of Multidrug-Resistant, Extensively Drug-Resistant, and Incurable Tuberculosis.” *The Lancet Respiratory Medicine* 5(4):291–360. doi:10.1016/S2213-2600(17)30079-6.

Dinas Kesehatan Provinsi Jawa Barat. 2024. *Laporan Kinerja Program Tuberkulosis Jawa Barat 2023*. Dinas Kesehatan Provinsi Jawa Barat.

Ehrt, Sabine, and Kyu Y. Rhee. 2023. “Metabolic Principles of Persistence and Pathogenesis in Mycobacterium Tuberculosis.” *Nature Reviews Microbiology* 21:5–18. doi:10.1038/s41579-022-00799-z.

Gupta, R., and S. P. Vyas. 2019. “Niosomal Drug Delivery: An Overview.” *Journal of Drug Targeting* 27(5–6):523–32. doi:10.1080/1061186X.2019.1608504.

Huang, C. 2023. “Inhalable Nanogel Formulation for Targeted Pulmonary TB Therapy.” *Advanced Drug Delivery Reviews* 200:114063. doi:10.1016/j.addr.2023.114063.

Kementerian Kesehatan RI. 2023. “Kemenkes: Kasus Tuberkulosis 2023 Meningkat Karena Deteksi Dini Dan Pelaporan Lebih Baik.”

Kementerian Kesehatan RI. 2024. *Profil Kesehatan Indonesia Tahun 2023*. Jakarta: Pusat Data dan Informasi Kesehatan, Kemenkes RI.

Koul, A., and Others. 2019. “The Role of ATP Synthase in Mycobacterium Tuberculosis and Its Inhibition by Bedaquiline.” *Nature Reviews Microbiology* 17(12):725–35. doi:10.1038/s41579-019-0231-0.

Lange, Christoph, Keertan Dheda, Dumitru Chesov, Anna Maria Mandalakas, Zarir Udwadia, and C. Robert Horsburgh Jr. 2019. “Management of Drug-Resistant Tuberculosis.” *The Lancet* 394(10202):953–66. doi:10.1016/S0140-6736(19)31882-3.

Lu, Y. 2020. “Dual-Drug Loaded PLGA Nanoparticles for Synergistic Therapy of MDR-TB.” *Materials Science and Engineering: C* 107:110277. doi:10.1016/j.msec.2019.110277.

Lun, S., and W. R. Bishai. 2019. “Characterization of Tuberculosis Drugs and Resistance Mechanisms Using Molecular and Pharmacokinetic Tools.” *Current Opinion in Pharmacology* 48:29–35. doi:10.1016/j.coph.2019.03.007.

Macêdo, D. C. dos S., I. D. L. Cavalcanti, S. M. de F. R. dos S. Medeiros, J. B. de Souza, M. C. de B. Lira Nogueira, and I. M. F. Cavalcanti. 2022. “Nanotechnology and Tuberculosis: An Old Disease with New Treatment Strategies.” *Tuberculosis* 135:hal. 102208. doi:10.1016/j.tube.2022.102208.

Maeda, H., and et al. 2020. “Enhanced Permeability and Retention (EPR) Effect in Nanomedicine: A Review.” *Journal of Controlled Release* 320:243–55. doi:10.1016/j.jconrel.2020.01.025.

Mishra, A. K., and et al. 2019. “Mycobacterial Lipid Components: Role in Pathogenesis and Potential as Therapeutic Targets.” *Frontiers in Microbiology* 10:2926. doi:10.3389/fmicb.2019.02926.

Müller, Rainer H., Karsten Mäder, and Sven Gohla. 2000. “Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery – a Review of the State of the Art.” *European Journal of Pharmaceutics and Biopharmaceutics* 50(1):161–77. doi:https://doi.org/10.1016/S0939-6411(00)00087-4.

Nahid, Payam, Susan E. Dorman, Narges Alipanah, Pennan M. Barry, Jan L. Brozek, Adithya Cattamanchi, Lelia H. Chaisson, Richard E. Chaisson, Charles L. Daley, Malgosia Grzemska, Julie M. Higashi, Christine S. Ho, Philip C. Hopewell, Salmaan A. Keshavjee, Christian Lienhardt, Richard Menzies, Cynthia Merrifield, Masahiro Narita, Rick O’Brien, Charles A. Peloquin, Ann Raftery, Jussi Saukkonen, H. Simon Schaaf, Giovanni Sotgiu, Jeffrey R. Starke, Giovanni Battista Migliori, and Andrew Vernon. 2016. “Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.” *Clinical Infectious Diseases* 63(7):e147–95.

World Health Organization. 2021. *Catalogue of Mutations in Mycobacterium Tuberculosis Complex and Their Association with Drug Resistance*. Geneva: World Health Organization.

Pandey, R. 2022. “Bedaquiline-Loaded Nanocarriers for Efficient Treatment of Multidrug-Resistant Tuberculosis.” *International Journal of Pharmaceutics* 612:121338. doi:10.1016/j.ijpharm.2022.121338.

Patra, Jayanta Kumar, Gitishree Das, Leonardo Fernandes Fraceto, Estefania Vangelie Ramos Campos, Maria Del Pilar Rodriguez-Torres, Laura Susana Acosta-Torres, Luis Armando Diaz-Torres, Renato Grillo, Mallappa Kumara Swamy, Shivesh Sharma, Solomon Habtemariam, and Han Seung Shin. 2018. “Nano Based Drug Delivery Systems: Recent Developments and Future Prospects.” *Journal of Nanobiotechnology* 16(1).

Peng, Chao, Yang Liu, Wei Zhang, Ming Chen, and Jian Li. 2022. “Structural Insights into ESAT-6/CFP-10 Complex and Its Role in Tuberculosis Virulence.” *Frontiers in Microbiology* 13:895632. doi:10.3389/fmicb.2022.895632.

Prego, C., and Others. 2010. “Chitosan-Based Nanostructures for Improving Drug Delivery.” *Journal of Drug Delivery Science and Technology* 20(5):331–38. doi:10.1016/S1773-2247(10)50065-6.

Sallam, Malik, Ali M. Alabbadi, Sarah Abdel-Razeq, Kareem Battah, Leen Malkawi, Mousa A. Al-Abbadi, and Azmi Mahafzah. 2022. “HIV Knowledge and Stigmatizing Attitude towards People Living with HIV/AIDS among Medical Students in Jordan.” *International Journal of Environmental Research and Public Health* 19(2). doi:10.3390/ijerph19020745.

Scherr, Nina, Srigowri Honnappa, Stefan Kunz, Peter Mueller, Radhika Jayachandran, Frank Winkler, Jan Pieters, and Marc O. Steinmetz. 2016. “Structural Basis for the Specific Inhibition of Protein Kinase G, a Virulence Factor of Mycobacterium Tuberculosis.” *Proceedings of the National Academy of Sciences* 113(1):E21–30. doi:10.1073/pnas.1510249113.

Sharma, A., and et al. 2020. “Nanoparticle-Based Delivery of Anti-Tuberculosis Drugs for Enhanced Efficacy.” *Pharmacological Reports* 72(4):1010–25. doi:10.1007/s43440-020-00098-z.

Sharma, Pankaj, Vinay Jain, and Saloni Jain. 2021. “Fabrication, Optimization And Evaluation Of Chronotropic Drug Deli-Very System Of Captopril.” *International Journal of Pharmaceutical Sciences and Research* 12(4):2203–10. doi:10.13040/IJPSR.0975-8232.12(4).2203-10.

Sharma, R., and et al. 2021. “Nanocarrier-Mediated Drug Delivery for Tuberculosis: Current Status and Future Prospects.” *Nanomedicine* 16(10):835–55. doi:10.2217/nnm-2021-0037.

Sullivan, T. J., and Others. 2023. “New Inhibitors of InhA for Treatment of Isoniazid-Resistant Tuberculosis.” *ACS Infectious Diseases* 9(1):134–44. doi:10.1021/acsinfecdis.2c00567.

Torchilin, Vladimir P. 2014. “Multifunctional, Stimuli-Sensitive Nanoparticulate Systems for Drug Delivery.” *Nature Reviews Drug Discovery* 13(11):813–27.

Ventola, C. L. 2017. “Progress in Nanomedicine: Targeted Drug Delivery in Clinical Applications.” *Pharmacy and Therapeutics* 42(12):742–55.

Wang, H., and et al. 2021. “Advances in Nanotechnology-Based Drug Delivery Systems for Tuberculosis Treatment.” *Journal of Nanobiotechnology* 19(1):335. doi:10.1186/s12951-021-01069-9.

WHO. 2023. *Global Tuberculosis Report 2023*. Geneva: World Health Organization.

World Health Organization. 2024. *Global Tuberculosis Report 2024*. Geneva: World Health Organization.

Zhao, Y., and et al. 2022. “Liposome-Based Drug Delivery Systems Targeting Macrophages in Tuberculosis Therapy.” *Journal of Controlled Release* 343:159–72. doi:10.1016/j.jconrel.2022.01.004.